Effect of food on capsule and granule formulations of selumetinib
Abstract Selumetinib is an oral, potent, and highly selective allosteric MEK1/2 inhibitor approved for the treatment of pediatric patients (aged ≥2 years) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. A granule formulation of selumetinib is under development...
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artykuł |
| Język: | English |
| Wydane: |
Wiley
2022-04-01
|
| Seria: | Clinical and Translational Science |
| Dostęp online: | https://doi.org/10.1111/cts.13209 |